These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of oxoplatinum and CBDCA on renal functions in rats.
    Author: Láznícková A, Semecký V, Láznícek M, Zubr V, Koksál J, Kvĕtina J.
    Journal: Neoplasma; 1989; 36(2):161-9. PubMed ID: 2654665.
    Abstract:
    Changes in renal function in rats after single-dose intravenous administration of CBDCA (cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) and oxoplatinum [cis-dichlorodiammine-trans-dihydroxo-platinum(IV)] at a dose of 20 mg/kg were determined and compared. Renal function was monitored by several determinations of effective renal plasma flow (ERPF), glomerular filtration rate (GRF), plasma creatinine and urea and urine beta 2-microglobulin. A significant reduction of ERPF and GRF and a significant increase of plasma creatinine and urea concentration after oxoplatinum treatment were found. On the other hand, no significant changes in renal function parameters were determined after CBDCA. The increase in beta 2-microglobulin amount in rat urine and polyuria persisted until the 14th day after oxoplatinum administration. Histological examination of the kidneys in the experimental animals revealed marked nephrotoxicity changes in the distal tubules after the single-dose administration of oxoplatinum. Administration of CBDCA did not produce pathological renal changes.
    [Abstract] [Full Text] [Related] [New Search]